Nadifloxacin API is a synthetic fluoroquinolone antibacterial active pharmaceutical ingredient used primarily in topical pharmaceutical preparations for dermatological applications. It belongs to the quinolone class of antibacterial agents and is particularly associated with the treatment of acne vulgaris and other susceptible bacterial skin infections.
Nadifloxacin is a fluorinated quinolone derivative with the molecular formula C19H21FN2O4 and molecular weight 348.37 g/mol. Its CAS number is 124858-35-1.
Nadifloxacin exhibits antibacterial activity by inhibiting bacterial enzymes involved in DNA replication and chromosome maintenance. Like other fluoroquinolone antibacterial agents, its activity is associated with inhibition of DNA gyrase and topoisomerase IV, enzymes that are essential for bacterial DNA synthesis.
This mechanism interferes with bacterial replication and contributes to the antibacterial effect of Nadifloxacin against susceptible microorganisms.
Nadifloxacin is primarily used in topical dermatological formulations, particularly for bacterial skin conditions such as acne vulgaris. It has been investigated and marketed in topical preparations because of its antibacterial activity against microorganisms associated with dermatological infections.
Its topical application makes Nadifloxacin relevant to pharmaceutical development involving dermatology, acne treatment and topical anti-infective products.
Nadifloxacin is commonly associated with topical formulations, including creams, gels and other dermatological dosage forms. The concentration and excipients used in a finished formulation depend on the specific approved product and market.
The API itself should be distinguished from the finished topical pharmaceutical product when entering CMS specifications.
Nadifloxacin is a synthetic organic compound containing fluorine, nitrogen and oxygen functional groups characteristic of its quinolone structure. Its physicochemical characteristics can influence solubility, formulation performance and analytical method development.
For commercial API documentation, physical appearance and other release characteristics should be taken from the applicable manufacturer's validated specification and Certificate of Analysis.
Nadifloxacin contains a quinolone carboxylic acid framework with fluorine substitution and additional nitrogen-containing structural features. Its defined chemical structure supports chromatographic and spectroscopic identification during pharmaceutical quality control.
Nadifloxacin API can be evaluated using validated analytical techniques such as HPLC, infrared spectroscopy and other appropriate physicochemical methods.
Important quality attributes may include:
The specific numerical acceptance criteria should be based on the applicable approved API specification or recognized pharmacopoeial standard. Numerical values should not be assumed where no authoritative universal specification is established.
Assay testing for Nadifloxacin is generally performed using a validated chromatographic procedure capable of accurately determining the content of the active substance and separating relevant impurities.
For commercial API release, the applicable Certificate of Analysis (CoA) should be used to confirm the actual batch-specific assay and impurity profile.
Nadifloxacin API is relevant to the development and manufacture of topical antibacterial and dermatological pharmaceutical products. Its established antibacterial mechanism and topical application profile make it useful for pharmaceutical research, formulation development, analytical development and manufacturing.
Nadifloxacin should be stored according to the applicable manufacturer's validated stability data and approved storage specification. Packaging should provide suitable protection from environmental conditions that may affect API quality.
Specific storage conditions should be confirmed from the current CoA, specification and technical documentation rather than assumed from generic API storage practices.
For commercial pharmaceutical applications, Nadifloxacin API should be manufactured and tested according to applicable GMP requirements and the relevant approved specification. Identity, assay, purity and impurity controls should be demonstrated through validated analytical procedures.
Where a pharmacopoeial standard applies to a particular market, the applicable current edition should be used for final release testing.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |